Summaries of health policy coverage from major news organizations
Baxter Inc. Recalls Burn Treatment After Product Tests Positive for ‘Rare’ HIV Strain
Baxter International Inc. yesterday announced a voluntary recall on one lot of Albumin Buminate 5%, a product used in hospitals to treat burn victims and patients in shock, after a test found HIV-2 in the product's plasma, Reuters reports. HIV-2 is "the main AIDS-producing virus in West Africa," but it is "rare" in the United States. Baxter spokesperson Tanya Tyska said that the lot is being recalled "for quality reasons, not safety reasons," and as a "precautionary measure only," as a viral inactivation pasteurization used in manufacturing the product "destroys HIV." She added that the product met FDA requirements for release in February and that no adverse effects have yet been reported with the lot. Tyska also noted that the experimental test that detects HIV genetic material used by Baxter is "a very sensitive test, so you can have a false positive" (Reuters, 7/23).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.